BIOXCEL THERAPEUTICS INC

BioXcel Therapeutics, Inc. (http://www.bioxceltherapeutics.com/) is a clinical stage biopharmaceutical company. The Company is focused on drug development that utilizes artificial intelligence (AI) approaches to develop therapies in neuroscience and immuno-oncology. The Company's two advanced clinical development programs are BXCL501, an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex), for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immune activator for the treatment of a rare form of prostate cancer and advanced solid tumors that are refractory or treatment-naive to checkpoint inhibitors.

• BIOXCEL THERAPEUTICS INC